The cystoisospora infection market is experiencing growth driven by advancements in diagnostic technologies and increasing awareness of parasitic infections. Cystoisospora, caused by the parasite Cystoisospora belli, primarily affects immunocompromised individuals, such as those living with HIV/AIDS, and can result in gastrointestinal symptoms like diarrhea, weight loss, and dehydration. Early detection is crucial for effective treatment and management, and advancements in diagnostic methods, such as PCR testing and enzyme-linked immunosorbent assays (ELISA), have significantly improved accuracy and speed in identifying the infection. The rising incidence of immunocompromised populations, especially in regions with high HIV prevalence like Latin America and sub-Saharan Africa, is further driving market demand. In North America, the growth of the market is also fueled by increasing recognition of co-infections like Cystoisospora among HIV-positive patients, with Cystoisospora accounting for 2-3% of AIDS-related illnesses. The introduction of rapid and non-invasive diagnostic tests has expanded accessibility, particularly in regions with limited healthcare resources. With the growing focus on improving healthcare infrastructure and diagnostic capabilities, the Cystoisospora infection market is set to expand further, providing valuable opportunities for innovative solutions in global healthcare.
